Mar 16, 2021 / 03:20PM GMT
Jay Olson - Oppenheimer & Co. Inc., Research Division - Executive Director & Senior Analyst
Hello, everyone, and welcome to Oppenheimer's 31st Annual Healthcare Conference. I'm Jay Olson, one of the biotech analysts at Oppenheimer, and I want to thank you all for joining us.
It's my pleasure to welcome Exelixis to our conference. And it's an honor to introduce Michael Morrissey, the CEO. (Operator Instructions) And with that, we'll get started. Thank you so much, Michael, for joining us.
Questions and Answers:
Jay Olson - Oppenheimer & Co. Inc., Research Division - Executive Director & Senior AnalystI thought maybe we'd open up with a few questions about your strong 2020 results. You delivered solid fourth quarter performance with $200 million of sales of cabo. And your 2021 guidance of $1 billion in revenues implies 35% year-over-year growth.
Can you just maybe talk about what sort of assumptions you factored into your 2021 revenue guidance? And what kind of recovery from COVID are you seeing so far this year?
Trustpilot
